ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
ALN-TTR02-003
Phase 2 small_molecule completed
Quick answer
ALN-TTR02 (patisiran) administered by intravenous (IV) infusion for TTR-mediated Amyloidosis is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- TTR-mediated Amyloidosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed